Citizens Jmp Forecasts Strong Price Appreciation for Avalo Therapeutics (NASDAQ:AVTX) Stock

Key Points

• Citizens Jmp raised its price target to $62 (from $52), implying ~183% upside, and several other brokers have issued buy/outperform ratings, leaving a MarketBeat consensus of "Moderate Buy" with a $48.14 target.
• Positive Phase 2 topline results for lead drug abdakibart (AVTX-009) met primary endpoints and Avalo plans to advance to a registrational Phase 3, driving a ~34.9% intraday jump on heavy volume.
• Capital raise: Avalo priced an underwritten offering of ~19.73M shares to raise roughly $375M at $17.75/share to fund Phase 3 and corporate needs, improving runway but diluting existing shareholders.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) had its price target boosted by stock analysts at Citizens Jmp from $52.00 to $62.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a "market outperform" rating on the stock. Citizens Jmp's target price suggests a potential upside of 182.67% from the company's current price.

Several other analysts also recently commented on AVTX. Citigroup reaffirmed an "outperform" rating on shares of Avalo Therapeutics in a report on Wednesday. Guggenheim began coverage on shares of Avalo Therapeutics in a report on Monday, February 2nd. They issued a "buy" rating and a $50.00 price objective on the stock. HC Wainwright upped their price objective on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the company a "buy" rating in a report on Wednesday, March 25th. BTIG Research increased their price target on shares of Avalo Therapeutics from $40.00 to $58.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, Wolfe Research initiated coverage on shares of Avalo Therapeutics in a report on Thursday, April 9th. They set an "outperform" rating and a $48.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $48.14.

Avalo Therapeutics Trading Up 34.9%

Shares of AVTX stock traded up $5.67 during trading hours on Wednesday, hitting $21.93. The company's stock had a trading volume of 12,472,242 shares, compared to its average volume of 774,942. The company has a 50 day moving average of $15.33 and a 200 day moving average of $16.24. The stock has a market cap of $585.86 million, a PE ratio of -3.90 and a beta of 0.78. Avalo Therapeutics has a 12-month low of $3.39 and a 12-month high of $23.71.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last released its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($1.54) by $1.17. The business had revenue of $0.06 million during the quarter, compared to analysts' expectations of ($0.21) million. As a group, analysts anticipate that Avalo Therapeutics will post -4.04 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Christopher Ryan Sullivan sold 8,457 shares of the stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $13.23, for a total transaction of $111,886.11. Following the sale, the chief financial officer directly owned 423 shares of the company's stock, valued at approximately $5,596.29. This represents a 95.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 3,970 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $18.01, for a total transaction of $71,499.70. Following the sale, the insider directly owned 3,622 shares in the company, valued at $65,232.22. This trade represents a 52.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 63,015 shares of company stock worth $987,326 over the last three months. 4.46% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Avalo Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Orbimed Advisors LLC raised its position in Avalo Therapeutics by 39.5% during the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company's stock worth $17,150,000 after acquiring an additional 382,300 shares during the period. Nantahala Capital Management LLC raised its position in Avalo Therapeutics by 24.1% during the third quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company's stock worth $15,697,000 after acquiring an additional 240,000 shares during the period. Affinity Asset Advisors LLC raised its position in Avalo Therapeutics by 4.5% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,051,054 shares of the company's stock worth $19,087,000 after acquiring an additional 44,837 shares during the period. Caligan Partners LP raised its position in Avalo Therapeutics by 5.8% during the fourth quarter. Caligan Partners LP now owns 881,533 shares of the company's stock worth $16,009,000 after acquiring an additional 48,200 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new position in Avalo Therapeutics during the third quarter worth $10,390,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics News Roundup

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: Positive Phase 2 topline results for abdakibart (AVTX-009) in moderate-to-severe hidradenitis suppurativa — the trial met its primary endpoint at both doses and the company plans to advance to a registrational Phase 3 program. Phase 2 LOTUS Results
• Positive Sentiment: BTIG raised its price target from $40 to $58 and maintained a Buy rating, signaling substantial upside expectations if clinical progress continues and supporting bullish analyst sentiment. BTIG Price Target Raise
• Positive Sentiment: Wedbush raised its target to $40 and set an Outperform rating, adding to the cluster of recent upbeat analyst views and higher consensus price targets for AVTX. Wedbush Upgrade
• Neutral Sentiment: Avalo priced an underwritten public offering of ~19.73M shares (plus pre-funded warrants), raising roughly $375M in gross proceeds at $17.75/share; proceeds are earmarked to fund abdakibart Phase 3 and corporate needs. The capital improves runway but is dilutive to existing shareholders; offering is expected to close May 7, 2026. Public Offering Pricing
• Negative Sentiment: Unusually large put-option activity: investors bought 5,095 puts (a ~201% increase vs. typical daily put volume), indicating some market participants are hedging or betting on near-term downside/volatility despite the positive news flow.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.